How much does it cost to bring a medical device to market?

The total cost varies widely by device class and regulatory pathway. Class II devices going through 510(k) clearance can reach market for under $5 million in well-structured cases, while Class III PMA devices can require $50 million or more through pivotal trial completion. These ranges are highly dependent on study design, manufacturing requirements, and regulatory complexity. No single figure applies to all devices.

What is the first funding source for a medical device startup?

Most medical device startups begin with founder capital and then pursue some combination of friends-and-family investment and non-dilutive grant funding, particularly SBIR and STTR grants through NIH, NSF, or the Department of Defense. Non-dilutive funding is valuable precisely because it does not require giving up equity at the earliest, highest-risk stage.

Do I need FDA clearance before raising a Series A?

Not necessarily. Some Series A rounds close before clearance, particularly if a company has compelling pivotal study data and a de-risked regulatory strategy. However, many medtech Series A investors prefer to fund after clearance because it removes the largest single risk. The answer depends on the device category, the investor's risk tolerance, and the quality of the regulatory strategy.

What do medtech investors look for in a founding team?

Most experienced medtech investors look for a combination of device engineering or scientific expertise, clinical domain knowledge (often a physician co-founder or advisor with strong institutional relationships), and at least one person who has navigated the FDA process before. Regulatory and clinical competence on the team is weighted heavily because it directly affects the probability of reaching clearance without a complete response letter.

What is the difference between dilutive and non-dilutive medtech funding?

Dilutive funding (equity investment from angels, VCs, or strategics) gives investors an ownership stake in your company. Non-dilutive funding (grants, contracts, loans) does not require giving up equity. SBIR and STTR grants are the most common non-dilutive source for early-stage medical device companies. They are also competitive: NIH SBIR Phase I acceptance rates have historically been in the range of 15 to 20 percent, though rates vary by institute and cycle.

How long does medtech fundraising take?

A seed round for a medical device company typically takes three to nine months from first LP conversation to close. A Series A can take six to twelve months. These timelines are longer than software startup fundraising because diligence involves FDA strategy review, IP analysis, and clinical validation review. Building runway to account for a six-to-nine-month fundraise is a common planning recommendation, though specific timelines vary by company and market conditions.

How to Fund a Medical Device Startup: A Stage-by-Stage Guide

Direct answer: Medical device startups typically raise capital across four stages: pre-seed (founders, friends and family, SBIR grants), seed (angel investors, seed funds), Series A (medtech venture capital), and growth rounds (strategic investors, corporate venture arms). Each stage is gated not just by traction metrics but by regulatory milestones: prototype completion, IDE or 510(k) submission, first-in-human data, and commercial clearance or approval. Investors price the round around where you sit on that regulatory timeline. (As of July 2026.)

Funding a medical device company is meaningfully different from funding a software startup. Revenue can be years away. The path to market is defined not by app store approval but by FDA review timelines and reimbursement coding. Investors who back medtech understand this. Your job in a fundraise is to show them you understand it too, and that you have a credible plan to reach the next derisking milestone on the least possible capital.

This guide explains the funding landscape by stage, what investors expect at each, and how regulatory progress maps to valuation.

Why Medical Device Fundraising Is Different

Three features of medtech separate it from most startup categories:

Long timelines before revenue. A Class II device moving through 510(k) clearance typically takes twelve to twenty-four months from the first submission to commercial clearance. A Class III device requiring Premarket Approval (PMA) can take three to seven years from first-in-human study to approval. During that window, a company has costs but no revenue. Investors price this in.

Regulatory milestones act as funding gates. The questions a seed investor asks are different from the questions a Series A investor asks, and the difference is almost entirely about where you are in the FDA process. A company with an IDE-approved study is a different risk profile than one with a cleared device and first commercial placements.

Reimbursement is a second regulatory path. Even after FDA clearance, a device needs a payer pathway. Whether that is an existing CPT code, a Category III tracking code, or a new code application through the AMA, it affects how quickly you can build revenue. Investors who understand medtech ask about reimbursement on day one.

Stage 1: Pre-Seed (Concept Through Prototype)

Typical raise: $250,000 to $2 million
Typical sources: Founders, friends and family, angel investors, SBIR/STTR grants, university technology transfer offices, incubators

At this stage you are building proof of concept, completing bench testing, and establishing IP. You probably do not yet have a path-to-market strategy documented in regulatory terms.

What moves pre-seed investors: A clinical problem with a large, definable population. A founding team with some combination of device engineering experience, clinical domain expertise, and regulatory familiarity. Evidence that the technology works at a bench level. Some sense of whether the device is likely Class II (510(k) pathway) or Class III (PMA pathway), because that determines how much capital you will need before commercialization.

Non-dilutive capital is particularly powerful here. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, administered through agencies including NIH and NSF, provide Phase I and Phase II grants whose amounts are set by SBA statutory guidelines that are adjusted annually for inflation. As of the April 2026 SBIR/STTR reauthorization, NIH may award up to approximately $323,090 for Phase I and $2,153,927 for Phase II without a separate SBA waiver, though individual NIH Institutes and Centers may set lower caps. Confirm the current guideline at https://seed.nih.gov before relying on a specific figure. Because these are grants and not equity investments, they do not dilute founders. They also serve as a form of third-party validation that can support the next equity round.

Stage 2: Seed Round (Feasibility Through First Regulatory Submission)

Typical raise: $2 million to $8 million
Typical sources: Angel investors with medtech experience, seed-stage medtech funds, family offices, strategic angel syndicates

By the seed stage, you typically have a functional prototype and are working toward your first formal regulatory interaction: a pre-submission meeting with the FDA, an IDE application for a pivotal study, or the preparation of a 510(k) submission.

What moves seed investors: The FDA pathway has been identified. You can articulate whether you are pursuing 510(k), De Novo, or PMA, and why. You have a credible regulatory counsel or regulatory affairs professional on the team or under contract. Your IP position is defensible. You have a clinical advisory board that includes physicians who would use the device.

Seed investors in medtech often look at how much capital you need to reach the next major derisking event: cleared by FDA, first commercial sale, or first reimbursable procedure. That number frames the round.

Stage 3: Series A (Post-Clearance or Pivotal Data)

Typical raise: $10 million to $30 million
Typical sources: Medtech-focused venture capital funds, some crossover funds, strategic investors beginning to track the company

For most Class II devices, Series A typically comes around FDA clearance or shortly after first commercial placements. For Class III devices, Series A may come after a successful pivotal study but before PMA submission.

What moves Series A investors: Evidence of clinical adoption. Early commercial traction, even if small in absolute terms. A reimbursement pathway that is documented, not theoretical. A regulatory affairs function that is capable of managing post-market obligations. A commercial leadership team (VP of Sales, medical affairs) that is either hired or identified.

Series A investors will run a detailed financial model that projects burn through commercialization. They are buying the proof that the device works clinically and that it can be sold commercially.

Stage 4: Growth Rounds and Strategic Capital

Typical raise: $30 million and above
Typical sources: Late-stage venture funds, growth equity, strategic investors (medtech OEMs, hospital systems, private equity), corporate venture capital arms

At this stage, the device is on the market and generating revenue. The question is how fast to scale. Strategic investors bring more than capital: they bring distribution networks, manufacturing relationships, and in some cases a potential acquisition pathway.

How Regulatory Progress Maps to Valuation

Investors in medtech price rounds around derisking events. Each major regulatory milestone removes a category of risk and, in theory, increases the company's value.

Milestone	Risk Removed	What Investors Typically Pay For Next
Prototype complete, bench data	Technical feasibility risk	Regulatory pathway clarity
Pre-submission meeting completed	Regulatory strategy risk	Submission quality
510(k) submitted	Submission risk	FDA response, clearance
510(k) cleared	Regulatory risk (Class II)	Clinical adoption, commercial launch
First commercial sales	Commercial feasibility risk	Reimbursement establishment
Reimbursement established	Revenue model risk	Scale

The table is a simplification. Some companies reach Series A before clearance if they have compelling pivotal data. Others clear FDA and still struggle to raise because reimbursement is unclear. But the structure helps you map where your company sits and what you need to demonstrate to get to the next round.

The Role of Marketing Readiness in Fundraising

Investors review your website, your pitch deck, your LinkedIn, and your published clinical claims. Regulatory accuracy in marketing materials is increasingly something sophisticated medtech investors notice. A company that says "FDA approved" for a 510(k)-cleared device, or makes clinical claims that exceed its cleared indications for use, signals a regulatory culture problem. That is not what you want an investor's due diligence team to find.

Building your marketing program in parallel with your regulatory strategy, with both connected to your cleared intended use, is part of demonstrating operational readiness to raise. It also means the day you receive clearance, your commercial messaging is ready to deploy.

Buzzbox Media works exclusively with medical device companies and healthcare organizations. If you are approaching a fundraise and want to pressure-test your marketing materials for regulatory accuracy and investor readiness, a 30-minute conversation is a reasonable starting point. Book at https://www.buzzboxmedia.com/book.